MARKET

NVUS

NVUS

Novus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9670
+0.0370
+3.98%
Pre Market: 0.9500 -0.017 -1.76% 08:42 09/28 EDT
OPEN
0.9300
PREV CLOSE
0.9300
HIGH
0.9900
LOW
0.9052
VOLUME
649.81K
TURNOVER
--
52 WEEK HIGH
1.450
52 WEEK LOW
0.2500
MARKET CAP
18.74M
P/E (TTM)
-0.8283
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Arbutus Reports Positive Hepatitis B Data, And Other News: The Good, Bad And Ugly Of Biopharma
Arbutus reports positive data for AB-729 for chronic hepatitis B.Marinus Pharmaceuticals hits primary endpoint in Genetic Epilepsy trial.Novus Therapeutics on upswing on Anelixis acquisition.
Seekingalpha · 5d ago
MRSN, FSLR among premarket losers
Strongbridge Biopharma (SBBP) -16% after pricing $25M share offering.NuCana (NCNA) -16% after pricing secondary offering.Dave & Buster's Entertainment (PLAY) -13%.Xenetic Biosciences (XBIO) -9%.Mersana Therapeutics (MRSN) -8% after reporting XMT-1536 data in ovarian cancer cohort.Inovio Pharmaceuticals (INO)
Seekingalpha · 09/17 12:17
Mid-Afternoon Market Update: Dow Jumps 300 Points; Fed Leaves Interest Rates Unchanged
Toward the end of trading Wednesday, the Dow traded up 1.1% to 28302.78 while the NASDAQ rose 0.06% to 11196.87. The S&P also rose, gaining 0.63% to 3,422.61.
Benzinga · 09/16 18:36
Mid-Day Market Update: Crude Oil Surges 4%; Eastman Kodak Shares Spike Higher
Midway through trading Wednesday, the Dow traded up 0.77% to 28,207.22 while the NASDAQ fell 0.05% to 11,184.63. The S&P also rose, gaining 0.43% to 3,415.98.
Benzinga · 09/16 16:01
Arrowhead Pharmaceuticals, Myomo leads healthcare gainers, Novus Therapeutics, Jounce Therapeutics among major losers
Gainers: Arrowhead Pharmaceuticals (ARWR) +46%, Myomo (MYO) +38%, AxoGen (AXGN) +15%, Covetrus (CVET) +14%, Inovio Pharmaceuticals (INO) +13%.Losers: Novus Therapeutics (NVUS) -13%, Jounce Therapeutics (JNCE) -10%, Syneos Health (SYNH) -7%, Verastem (VSTM) -5%, Evogene (EVGN) -5%.
Seekingalpha · 09/16 15:00
Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences
Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences
Business Wire · 09/15 21:56
Why Novus Therapeutics Is Trading Higher Today
Novus Therapeutics (NASDAQ: NVUS) shares are trading higher on Tuesday after the company announced the purchase of Anelixis Therapeutics.Novus Therapeutics is engaged in the biotechnology sector. As a pharmaceutical company it is focused on the acquisition, development, and commercialization of ear,
Benzinga · 09/15 19:24
Novus Therapeutics Explodes 166% On Anelixis Deal, Capital Raise
Novus Therapeutics (NVUS) has announced it has completed the acquisition of Anelixis Therapeutics, a privately held clinical stage biotech developing a next generation anti-CD40 Ligand (CD40L) antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative
SmarterAnalyst · 09/15 08:25
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVUS. Analyze the recent business situations of Novus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVUS stock price target is 1.317 with a high estimate of 2.000 and a low estimate of 0.4500.
EPS
Institutional Holdings
Institutions: 31
Institutional Holdings: 6.77M
% Owned: 34.91%
Shares Outstanding: 19.38M
TypeInstitutionsShares
Increased
5
1.30M
New
12
-576.79K
Decreased
1
24.18K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.88%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Independent Director
Keith Katkin
President/Chief Scientific Officer
Steven Perrin
Chief Executive Officer/Director
David-Alexandre Gros
Chief Financial Officer/Chief Accounting Officer
Jon Kuwahara
Director
John McBride
Independent Director
Gary Lyons
Independent Director
Walter Ogier
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NVUS
Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Novus Therapeutics Inc stock information, including NASDAQ:NVUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVUS stock methods without spending real money on the virtual paper trading platform.